Reviewing Salix Pharmaceuticals (SLXP) & Aimmune Therapeutics (AIMT)

Salix Pharmaceuticals (NASDAQ: SLXP) and Aimmune Therapeutics (NASDAQ:AIMT) are both specialty & advanced pharmaceuticals companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Salix Pharmaceuticals and Aimmune Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Salix Pharmaceuticals -2,134.34% -305.24% -25.83%
Aimmune Therapeutics N/A -46.18% -43.28%

Valuation and Earnings

This table compares Salix Pharmaceuticals and Aimmune Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Salix Pharmaceuticals N/A N/A N/A ($6.51) -26.55
Aimmune Therapeutics N/A N/A -$80.82 million ($2.35) -15.05

Salix Pharmaceuticals is trading at a lower price-to-earnings ratio than Aimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Salix Pharmaceuticals and Aimmune Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Salix Pharmaceuticals 0 0 0 0 N/A
Aimmune Therapeutics 0 0 4 0 3.00

Aimmune Therapeutics has a consensus target price of $58.75, suggesting a potential upside of 66.15%. Given Aimmune Therapeutics’ higher probable upside, analysts plainly believe Aimmune Therapeutics is more favorable than Salix Pharmaceuticals.

Risk and Volatility

Salix Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Aimmune Therapeutics has a beta of -0.66, suggesting that its share price is 166% less volatile than the S&P 500.

Insider and Institutional Ownership

73.3% of Aimmune Therapeutics shares are held by institutional investors. 17.6% of Aimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aimmune Therapeutics beats Salix Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Salix Pharmaceuticals Company Profile

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.